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INTRODUCTION
ANDPHARMACOLOGICALISSUES
Together with amphetamines and 3,4-methylenedi-
oxymethamphetamine (MDMA, ecstasy), metham-
phetamine (pharmaceutically referred to as methyl-
amphetamine or desoxyephedrine) is usually ranked 
in the group of amphetamine-type stimulants (ATS). 
It is a psychostimulant drug used primarily for recrea-
tional purposes, but is sometimes prescribed for med-
ical reasons. Methamphetamine found on the street 
is a colorless crystalline solid, often adulterated with 
chemicals that were used to synthesize it. “Crystal 
meth”, otherwise known as methamphetamine 
hydrochloride (“ice”, “glass”, “Tina”, “Christine”, 
“yaba” and “crazy medicine”), is a purified form of 
methamphetamine. Methamphetamine hydrochlo-
ride is the formulation of methamphetamine that 
can be smoked. The unprocessed methamphetamine, 
when smoked, may be far less rewarding as the tem-
perature needed to vaporise the drug also inactivates 
most of the active substance [1].
Methamphetamine is a potent central nervous 
system stimulant; it causes both the noradrenalin 
and the dopamine transporters to reverse their di-
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Summary. “Ice”, “crystal meth”, is the smokable form of methamphetamine hydrochloride. This 
paper will comment on the pharmacological, epidemiological, clinical and social issues related to 
smoking the drug as opposed to either its injection or ingestion. Furthermore, some data related to 
amphetamines/methamphetamines consumption, request for treatment, seizures, related offences 
and deaths in the UK (1990-2002) will be offered here. Peak rates, for most indicators, were reached 
at the end of the ’90s, to fall down in the following years. The only indicator which seemed not to 
show any declining rates is number of deaths, but this may be related to a more general increase in 
stimulant death rates recently observed in the UK. It is argued that methamphetamines, and par-
ticularly “crystal meth”, could reach the same prevalence levels of use in the UK as it is already in 
the US but recent reclassification of the drug to Class A in the UK could help to better control this 
emerging issue.
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Riassunto (Stimolanti amfetamino-simili fumabili – “ice”, “crystal meth” – e non fumabili; aspetti di 
farmacologia clinica e di epidemiologia, con particolare riferimento al Regno Unito). “Ice” e “crystal 
meth” sono i nomi da strada con cui è conosciuta la formulazione fumabile della metamfetamina 
cloridrato. Il lavoro commenta in merito agli aspetti di farmacologia clinica, epidemiologici e sociali 
della formulazione fumabile rispetto alle altre. Inoltre, vengono presentati alcuni dati relativi al con-
sumo, richiesta di trattamento, sequestri, reati connessi e decessi correlati all’uso di amfetamina/me-
tamfetamina nel Regno Unito (1990-2002). I valori più elevati di questi indicatori si sono osservati 
nella seconda metà degli anni ’90, per poi andare incontro ad un decremento. L’unico indicatore che 
non mostra declino si è dimostrato essere quello relativo al numero di decessi associati all’uso della 
sostanza, un dato che probabilmente va messo in relazione al più generale aumento di decessi da 
stimolanti osservato negli ultimi anni nel Regno Unito. Viene suggerito che la diffusione della me-
tamfetamina, ed in particolare della “crystal meth”, potrebbe raggiungere nel Regno Unito i livelli 
che già si osservano negli USA. La recente riclassificazione della metamfetamina, tuttavia, potrebbe 
aiutare a controllare questo problema emergente. 
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rection of  action, causing increased stimulation of 
post-synaptic receptors. Methamphetamine also 
indirectly prevents the reuptake of  these neuro-
transmitters, causing them to remain in the synap-
tic cleft for a prolonged period. The serotonin level 
is virtually not affected [2]. The acute effects of  the 
drug closely resemble the physiological and psy-
chological effects of  an adrenaline-provoked fight-
or-flight response, including increased heart rate 
and blood pressure, vasoconstriction, bronchodi-
lation, and hyperglycemia (http://en.wikipedia.
org/wiki/Crystal_meth 2006). Users experience an 
increase in focus, increased mental alertness, and 
the elimination of  fatigue, as well as a decrease in 
appetite.
Short term tolerance to methamphetamine is caused 
by depleted levels of neurotransmitters within the 
vesicles available for release into the synaptic cleft fol-
lowing subsequent reuse (tachyphylaxis). Short term 
tolerance typically lasts 2-3 days, until neurotrans-
mitter levels are fully restored. Prolonged overstimu-
lation of dopamine (DA) receptors caused by meth-
amphetamine may eventually cause the receptors to 
down regulate in order to compensate for increased 
levels of DA within the synaptic cleft [3].
“CRYSTALMETH”MANUFACTURE
Unlike amphetamine, methamphetamine is quite 
easily made in a clandestine home laboratory. One 
of  the more common methods involves the use of 
L-ephedrine, which is reduced to methampheta-
mine using hydriodic acid and red phosphorus [4]. 
The product of  this reaction, which can also be 
carried out with different acids and substances like 
chloroephedrine or methylephedrine, is pure D-
methamphetamine, which is both lipid-soluble and 
volatile. To contrast its vaporization, producers 
use hydrochloride to convert it to the water-soluble 
methamphetamine hydrochloride powder [5]. The 
term “ice” was coined in the Far East due to the 
large crystals that are formed during the reduction 
process [6]. To make the “ice”, methamphetamine 
hydrochloride is added slowly to water and then 
brought to a temperature of  just under 100°C, thus 
forming a super-saturated solution. The solution 
is then allowed to cool and the “ice” precipitates 
from the solution itself  [5]. The ephedrine required 
for manufacture is usually extracted from over-the-
counter cold and flu medicines although it can also 
be obtained from the black market [7]. Until the 
early 1990s, methamphetamine was made mostly in 
clandestine labs run by drug traffickers in Mexico 
and California. These areas are still the largest 
producers for the US market. Since then, however, 
authorities have discovered increasing numbers 
of  small-scale methamphetamine labs all over the 
United States. Recently, mobile and motel-based 
methamphetamine labs have caught the atten-
tion of  both the news media and law enforcement 
agencies. The labs can cause explosions and fires, 
as well as expose the public to hazardous chemi-
cals. In addition to these issues, individuals who 
manufacture methamphetamine are often harmed 
by toxic gases. Many police forces have responded 
by creating a specialized task force educated in re-
sponding to persons involved in methamphetamine 
production.
EPIDEMIOLOGICALISSUES
INTHEEUANDOUTSIDE
No large-scale literature is available in terms of 
the epidemiology of the smokable form of meth-
amphetamine, and so both this and the following 
UK section will be based on the epidemiology of 
amphetamines and methamphetamine – e.g., ATS 
drugs, excluding MDMA/ecstasy and ecstasy-like 
drugs – misuse. 
After cannabis, amphetamines are the most com-
monly used illegal substances. According to recent 
surveys [8], among all adults (15-64 years), lifetime 
experience of amphetamine use in EU Member 
States ranges from 0.1% to 12% (with UK reporting 
the highest consumption levels). Recent use is clear-
ly lower, ranging from 0% to 1.5%, with Denmark, 
Estonia and the United Kingdom at the higher end 
of the scale. A similar picture emerges among the 
young adults group (15-34 years) in population sur-
veys, among which group lifetime experience of am-
phetamine use ranges from 0.1% to 10%, with the 
UK reporting the highest rates.
According to the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), am-
phetamine is much more available in Europe than 
methamphetamine but, on a global level, levels of 
methamphetamine are rising [8]. In Europe, the 
main country that uses methamphetamine is the 
Czech Republic. Amphetamine use is increasing in 
virtually every EU country. In Europe, the main pro-
ducer of methamphetamine is the Czech Republic, 
followed by Germany, Lithuania and Norway. On a 
global scale the biggest producers are in South East 
Asia (China, Thailand and the Philippines) followed 
by North America [8]. Within Asia, there are coun-
tries, including Thailand, Cambodia and Indonesia, 
which produce mainly methamphetamine tablets 
and others (i.e., Japan, Northern China, Taiwan, 
Philippines) which produce mainly “crystal meth” 
[9]. It is estimated that about 332 tonnes of amphet-
amine-like substances (mainly methamphetamine), 
excluding ecstasy, were produced in 2003 [9]. It has 
been estimated that approximately 26 million peo-
ple worldwide used amphetamine-like substances in 
2003 [9], a number higher than that of the users of 
cocaine and heroin combined. In 2003, the global 
amphetamine market (excluding ecstasy) was worth 
$28.3 billion at a consumer price level [9]. In taking 
into account the world amphetamine production 
level of 332 tonnes, it can be obtained a figure of 
about $85,000 per amphetamine kilogram, or about 
$20 for a 0.25 gram dose. 
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AMPHETAMINES,METHAMPHETAMINES
AND“CRYSTALMETH”CONSUMPTION,
REQUESTFORTREATMENT,SEIZURES,
RELATEDOFFENCESANDDEATHS
INTHEUK(1990-2002)
Some descriptive and correlational observations, 
covering the period January 1990 to December 2002, 
are given in Figure 1. Death figures were obtained 
from the Office of National Statistics (ONS, which 
is responsible for the General Register Office for 
England & Wales), from the General Register Office 
for Scotland (GROS) and from the Department 
of Health, Social Services and Personal Safety for 
Northern Ireland, which has direct access to the da-
ta files at the General Register Office for Northern 
Ireland (GRONI). The figures given here were total 
mentions of ATS drugs, excluding MDMA/ecstasy. 
They represented deaths from any cause where the 
presence of ATS drugs was also detected on death 
certificates for fatalities occurring in the years 
1990-2002. Drug-related deaths were defined us-
ing the standard definition employed by the Office 
of National Statistics [10]. The number of persons 
dealt with for drug offences involving ATS drugs in 
the UK and the number of ATS seizures in the UK 
were taken from the Home Office Statistical Bulletins 
[11]. Information on seizures is reported to the 
Home Office by: Police forces, the National Crime 
Squad and Revenue and Customs. Regional Drug 
Misuse Database (RDMD) data, which provide in-
formation on rates of ATS drugs’ use amongst those 
presenting for treatment for drug dependence, were 
taken from the appropriate Department of Health 
publications [12]. 
As it can be seen from Figure 1, the prevalence of 
recent (use in the last 12 months) ATS drugs’ con-
sumption levels are higher to those reported in oth-
er countries but overall rates are continuing to fall. 
Peak rates, for most indicators, were reached at the 
end of the ’90s, to fall down in the following years. 
The only indicator which seems not to show any de-
clining rates is the number of deaths. In line with 
previous observations, however [13, 14] this increase 
may be related to a more general increase in stimu-
lant death rates. Reasons behind this increase may 
include: increase in ATS drugs use in a polydrug, 
including opiates/opioids [15], misuse context, and 
higher reporting rates of ATS drugs on death certifi-
cates. Alternatively, since only a minority of fatali-
ties involved an ATS drugs mono-intoxication, in-
crease in death mentions here observed might reflect 
increase in fatalities related to other drugs, such as 
ecstasy [13]. Huge media interest surrounded some 
of the high profile cases of ATS-related incidents 
occurring in the last decade or so in the UK and this 
may have increased awareness of the possible con-
sequences of drug consumption. In turn, this may 
have led to improved surveillance, monitoring and 
recording of the substance in investigations of sud-
den and/or unexpected deaths (Table 1).
ROUTESOFADMINISTRATION,
CHARACTERISTICSOF
“CRYSTALMETH”USERS
The usual route for medical use is oral administra-
tion. In recreational use it can be swallowed, snorted, 
smoked, dissolved in water and injected, inserted 
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Fig.1 | Amphetamine-type stimulants 
consumption, request for treatment, 
seizures, related offences and deaths 
in the UK (1990-2002).
Legenda: No of seizures: number of seizures carried out in the 1990-2002 time frame. BCS last year: British Crime Survey results, e.g., prevalence of ATS 
use at least once within last year. No of FG & cautioned: number of individuals found guilty and cautioned for ATS drugs possession, trafficking etc. RDMD 
episodes: Regional Drug Misuse Database episodes, e.g., rates of ATS drugs’ use amongst those presenting for treatment for drug dependence. Deaths (E&W): 
number of ATS drugs mentions on death certificates over the period 1990-2002 (England and Wales only). Information on last year use of ATS drugs recorded 
by the British Crime Survey (BCS) was taken from the appropriate Home Office publications. The drug misuse self-completion component of the British Crime 
Survey asks about drug use over the respondent’s lifetime, in the last year and in the last month; the indicator presented here referred to respondents’ use of ATS 
drugs in the last year. Figures related to general household surveys conducted in England and Wales only and were the results for respondents aged 16-29 for the 
sweeps in 1992, 1994, 1996 and 1998. The figures for intermediate years e.g., 1995 were the mid-point between the rates for the year preceding and year following 
e.g., 1994 and 1996. Please note that different figures have been appropriately modified, as above specified, to adequately fit the table graphics.
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anally (with or without dissolution in water), or into 
the urethra [16]. In general, both injecting and smok-
ing are the fastest mechanism followed by snorting, 
anal insertion, and swallowing.
The advantage of the smoked form, compared to its 
oral formulation, is the greater bioavailability offered. 
The bioavailability of smoked methamphetamine hy-
drochloride is 90.3 ± 10.4%, whilst the bioavailabil-
ity of oral methamphetamine is 67.2 ± 3.1%. [17-19]. 
Mean plasma half-life of smokable methamphetamine 
hydrochloride would be 11.1 hours, whilst ampheta-
mine half life would be in the range of 5 to 30 hours, 
depending on the urinary pH [1]. Between 37 and 45% 
of methamphetamine is excreted in urines as meth-
amphetamine and 7% as amphetamine [17]. As meth-
amphetamine is a weak base this is greatly affected by 
the urine pH. In acidic urines, up to 76% is excreted as 
methamphetamine and 7% as amphetamine, whilst in 
alkali urines as little as 2% may be excreted as meth-
amphetamine and 0.1% as amphetamine [20].
From the pharmacological data, it can be argued 
that a drug with a high bioavailability will have a more 
pronounced psychoactive effect, perhaps explaining 
the popularity of smokable methamphetamine. In 
fact, with this formulation, it can be achieved a bio-
availability of approximately 90%. This is very close 
to the 100% level which is characteristic of an intrave-
nously injectable formulation, without however run-
ning the risks associated with intravenous drug use.
Methamphetamine is commonly smoked in glass 
pipes, or in aluminum foil heated by a flame un-
derneath. In the UK, this method is also known as 
chasing the white dragon. Methamphetamine must 
be heated (not burned) to cause the desired smoke. 
Very little research has focused on anal insertion as 
a method. If  enough methamphetamine is taken so 
that not all of it is completely dissolved, abrasion 
of any prophylactic devices (such as condoms) used 
during sex can occur due to friction with undissolved 
meth crystals. This can contribute to breakage of the 
prophylactic, and increased risk of disease transmis-
sion. Up to 1 in 5 gay men in London have been recent-
ly reported to be using smokable methamphetamine 
(http://news.bbc.co.uk/1/hi/uk/4604047.stm). The use 
of “crystal meth” may cause disinhibition, impair-
ment in judgement, decreased condom use, prostitu-
tion and intercourse with known intravenous drug 
users by both heterosexual and homosexual people 
(http://news.bbc.co.uk/1/hi/uk/4604047.stm). Part 
of the reason for its popularity in this users’ group 
is its apparent aphrodisiac effect [21]. From a physi-
ological point of view, “crystal meth” may cause 
increased libido, delayed ejaculation, longer inter-
course duration, and decreased humoral secretions 
(“raw genitalia”), and this might contribute to a 
higher chance of infection [22]. The sexual effects of 
these drugs are one of the main positive reinforcers 
for their use [23, 24]. Interestingly, copulatory be-
haviour, including mounting, intromission and ejac-
ulation, is reduced in male rats administered with 
intraperitoneal methamphetamine hydrochloride 
[25]. Methamphetamine is different from the other 
ATS drugs, including ecstasy, despite these drugs of-
ten being taken in the same setting. “Crystal meth” 
is used to increase energy and alertness while ecstasy 
is used cause euphoria and a sense of belonging to a 
group but doesn’t cause any of the sexual effects of 
methamphetamine [26]. 
MEDICALANDPSYCHIATRICSIDEEFFECTS
The systemic side effects of “crystal meth” arise 
from its peripheral actions as it acts as an indirect 
sympathomimetic amine and may include: tachycar-
dia, hypertension, palpitations, sweating, dry mouth, 
decreased gastroenteric motility and dilated pupils. 
Table1 | Amphetamine indicators, 1990-2002 
Year n. of seizures 
(100s)
n. found guilty & 
cautioned (100s)
n. of deaths in 
England & Wales
Last year use, 
British crime 
survey (% x 10)
RDMD episodes 
(100s)
1990 46.29 23.30 n.a. n.a. n.a.
1991 68.21 35.32 n.a. n.a. n.a.
1992 105.70 56.53 n.a. 40 n.a.
1993 117.30 76.22 36 55 44.62
1994 130.34 85.46 46 70 43.97
1995 154.62 103.64 48 75 51.82
1996 182.76 129.21 47 80 55.29
1997 186.09 134.74 50 80 48.97
1998 186.30 151.20 71 80 56.78
1999 133.93 122.50 80 65 54.87
2000 70.73 66.90 59 50 32.06
2001 68.20 49.50 83 50 26.20
2002 69.80 58.20 93 37 n.a.
n.a.: data not available.
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Methamphetamine appears to cause cardiomyopa-
thy, in a way similar to that induced by cocaine [27], 
pulmonary oedema and myocardial infarction [28], 
and ischaemic and haemorrhagic strokes [29]. 
Methamphetamine use may be associated with 
schizophrenia-like acute psychotic episodes, prob-
ably due to its actions on the mesolimbic and meso-
cortical dopaminergic pathways. Users with a high 
family vulnerability for schizophrenia are more 
likely to experience psychotic episodes than users 
without this vulnerability [30]. In an effort to iden-
tify which areas of the brain were affected by am-
phetamine-induced psychosis, Buffenstein et al [31] 
used single photon emission computer tomography 
(SPECT) and found that 76% of amphetamine mis-
users showed focal perfusion deficits in the frontal, 
parietal and temporal lobes. Another study looked 
at qualitative differences in psychosis induced by 
smoking “crystal meth” compared to injecting it. It 
was found that smokers experienced their first psy-
chotic episode before injectors but showed fewer au-
ditory hallucinations [32]. 
Typically, “crystal meth” misuse can have a det-
rimental effect on teeth. In a few months, healthy 
teeth can turn greyish-brown, twist and begin to 
fall out, taking on a peculiar texture less like that 
of hard enamel [33]. The mechanism is thought to 
be due to the dry mouth caused by “crystal meth” 
sympathomimetic action, which in turn makes users 
thirsty and crave sugary soft drinks. The problem is 
likely to be further aggravated by the caustic sub-
stances used in the drug preparation, such as lithium 
and red phosphorus [33] (Table 2).
LEGALISSUES
INTHEWESTERNWORLDCOUNTRIES
The legal issues in the western world countries are 
described as follows [3]:
-  Australia. Methamphetamine is a controlled drug 
permitting some medical use, but is otherwise out-
lawed.
-  Canada. Methamphetamine is not approved for 
medical use in Canada. As of 2005, it falls under 
the Controlled Drugs and Substances Act. The 
maximum penalty for the production and distri-
bution is imprisonment for life.
-  South Africa. In South Africa methamphetamine 
is listed as undesirable dependence-producing 
substances in the Drugs and Drug Trafficking 
Act, 1992 (Act No 140 of 1992; http://www.saps.
gov.za/drugs/ats.htm). 
-  United States. Methamphetamine is classified as 
a controlled substance by the Drug Enforcement 
Agency under the Convention on Psychotropic 
Substances (http://www.incb.org/pdf/e/list/green.
pdf). While there is technically no difference be-
tween the laws regarding methamphetamine and 
other controlled stimulants, most medical profes-
sionals are averse to prescribing it due to its status 
in society. Methamphetamine is legally marketed 
in the United States; generic formulations of the 
drug are also available. Methamphetamine has be-
come a major focus of the “war on drugs” in the 
US in recent years. In some areas of the United 
States, manufacturing methamphetamine is pun-
ishable by a mandatory 10-year prison sentence. 
-  UK. In the UK, methamphetamine was reclassi-
fied only very recently. In fact, on 14 June 2006, 
Under-Secretary of State for Policing, Security 
and Community Safety in the Home Office an-
nounced that methamphetamine was to be reclas-
sified as a Class A drug (i.e., like heroin, cocaine, 
ecstasy etc) following a recommendation made 
by the Advisory Council on the Misuse of Drugs 
(ACMD). The reasons for the ACMD’s recom-
mendation were that there is now evidence that 
the drug is becoming more widely used within the 
United Kingdom, that the police have become 
aware of several illicit laboratories synthesizing the 
drug, and also that media interest in it has grown.
CONCLUSIONS
Although in Europe amphetamines are used pre-
dominantly over methamphetamines, in other parts 
of the world it appears to be the opposite. One 
might argue that a more hard-line approach to am-
phetamines may make the producers risks outweigh 
their profits thereby discouraging them. From both 
a chemical and a pharmacological point of view, 
methamphetamine and ecstasy are not dissimilar and 
yet ecstasy has carried far greater legal punishment 
up to recently. The smokable form may have a simi-
lar effect to cocaine but with a much longer “high’ 
due to its greater half-life. According to the UN 
Table2 | Side-effects associated with amphetamine use
Common side effects 
Diarrhoea, nausea 
Loss of appetite, insomnia, restlessness, tremor, jaw-clenching
Agitation, compulsive fascination with repetitive tasks (“punding”)
Talkativeness, irritability, panic attacks 
Increased libido 
Dilated pupils
Side effects associated with chronic use
Addiction
Weight loss
Withdrawal-related depression and anhedonia 
Erectile dysfunction (“crystal cock”)
Tooth decay (“meth mouth”)
Amphetamine psychosis 
Formication (sensation of flesh crawling with bugs, with possible 
associated compulsive picking and infected sores)
Long-term cognitive impairment (possibly due to neurotoxicity)
Paranoia, delusions, hallucinations
Kidney damage
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International Narcotics Control Board, metham-
phetamine is “emerging as the world’s biggest drug 
problem” (http://www.incb.org/pdf/e/list/green.pdf). 
And yet the British Broadcasting Communication 
(BBC) presents only with 10 articles on the subject 
(search results carried out in May 2006 for “crystal 
meth”), compared to the innumerably more articles 
on heroin, cocaine and ecstasy. Methamphetamines, 
and particularly “crystal meth”, could quite easily 
reach the same prevalence levels of use in the UK 
as it is already in the US. This process may be facili-
tated by the lack of stigma attached to this relatively 
unknown drug and its low cost. Apart from better 
education, specifically about its negative effects, it is 
felt here that the recent reclassification of the drug 
to Class A in the UK could help to better control 
this emerging issue. 
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